# Cemiplimab in AlloSCT/SOT Recipients With CSCC

> **NCT04339062** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Cutaneous Squamous Cell Carcinoma
- Advanced Cancer

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Everolimus
- **DRUG:** Sirolimus
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT04339062
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-03
- **Primary completion:** 2023-06-12
- **Final completion:** 2025-03-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04339062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04339062, "Cemiplimab in AlloSCT/SOT Recipients With CSCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04339062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*